Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Prothena (PRTA) Stock Price

News articles about Prothena (NASDAQ:PRTA) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Prothena earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.0738772131947 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of equities analysts have recently issued reports on PRTA shares. Deutsche Bank reiterated a “buy” rating on shares of Prothena in a research report on Sunday, October 1st. Royal Bank of Canada reissued a “buy” rating on shares of Prothena in a research note on Friday, September 29th. ValuEngine downgraded shares of Prothena from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. SunTrust Banks reaffirmed a “buy” rating and issued a $75.00 target price on shares of Prothena in a research note on Monday, October 2nd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $65.00 price target on shares of Prothena in a report on Wednesday, December 20th. Three analysts have rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $75.58.

Prothena (PRTA) opened at $39.62 on Friday. The firm has a market cap of $1,500.00, a PE ratio of -9.34 and a beta of 2.43. Prothena has a 1 year low of $34.85 and a 1 year high of $70.00.

Prothena (NASDAQ:PRTA) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) EPS for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.04. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. During the same period last year, the firm earned ($1.26) earnings per share. Prothena’s revenue for the quarter was down 33.6% compared to the same quarter last year. equities analysts anticipate that Prothena will post -4.27 EPS for the current fiscal year.

WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at

Prothena Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with's FREE daily email newsletter.

Leave a Reply